Objectives To compare the efficacy, safety and effects on quality of life of different ALK-
inhibitors for global and Asian patients with advanced ALK-positive non-small-cell lung …

Because of lacking of head-to-head comparison among lorlatinib, alectinib and brigatinib for
patients with ALK inhibitor–naive or untreated (ALK inhibitor-naive and chemotherapy …

Purpose The current study was carried out to compare the effectiveness and safety of
different ALK inhibitors in treating ALK+ NSCLC. Methods Progression‐free survival (PFS) …

Background Mature progression-free survival (PFS) data from the phase III J-ALEX study
showed superiority for alectinib versus crizotinib [hazard ratio (HR) 0.37, 95% confidence …

Objective To date, no direct comparisons have compared the effectiveness of all ALK
inhibitors (ALKis) against ALK‐positive non‐small cell lung cancer (NSCLC). The aim of the …

Background Anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs) are mainly
used in the treatment of ALK-positive advanced non-small cell lung cancer (NSCLC), but a …

This study aimed to evaluate the efficacy of anaplastic lymphoma kinase (ALK)-inhibitors in
the treatment of ALK-positive non-small cell lung cancer (NSCLC) by using a meta-analysis …

Background: Crizotinib and alectinib are the 2 most commonly used anaplastic lymphoma
kinase (ALK) inhibitors for ALK-positive non-small cell lung cancer (NSCLC). We compared …

Objective To systematically evaluate the efficacy and safety of alectinib versus crizotinib in
the treatment of anaplastic lymphoma kinase (ALK) positive non-small-cell lung cancer …

Abstract Objectives The J-ALEX study compared the efficacy and safety of alectinib with
crizotinib in Japanese patients with advanced ALK-positive non-small-cell lung cancer …